Mance E. Buttram Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI

Associate Professor

University of Arkansas

Last publication 2026 Last refreshed 2026-05-22

faculty

19 h-index 129 pubs 1,230 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Mance E. Buttram's research focuses on substance use disorders, particularly opioid use disorder, and its co-occurring issues, including HIV infections and sexually transmitted infections. Buttram currently serves as PI on a $137,885 NIH/National Institute on Drug Abuse grant examining the concomitant non-medical use of gabapentin and opioids.

Recent publications investigate the associations between transactional sex and sexually transmitted infections among individuals with opioid use disorder, the impact of socio-environmental factors on doxycycline post-exposure prophylaxis awareness, and the nonmedical use of gabapentin and opioid agonist medications. Other work examines kratom-related state policy environments and kratom use, gabapentin use among individuals initiating buprenorphine treatment, increasing rates of buprenorphine diversion, and motivations for gabapentin use with opioid agonist medications. Buttram has also studied geographic and racial/ethnic differences in access to methamphetamine detoxification services.

Buttram's scholarship metrics include an h-index of 19, 129 total publications, and 1,214 total citations. Buttram leads a research group at the University of Arkansas at Fayetteville and collaborates with researchers including Krishen D. Samuel, Yamilka Stivers, Corinne L. Chandler, and Kayla E. Simon.

Metrics

h-index: 19
Publications: 129
Citations: 1,230

Selected Publications

Gabapentin-Related State Policies and Associations with Gabapentin Non-Medical Use Among a Nationally Representative Population in the United States (2025)

1 citation DOI OpenAlex
Pharmaceutical stimulant diversion, 2002–2022: data from a national sample of law enforcement and regulatory agencies in the US (2025)

DOI OpenAlex
It’s Like Disney … You Have to Find Them a Fantasy: Latino Sexual Minority Men at the Intersection of Tourism, Sex, Drug Use, and HIV in Miami-South Beach (2025)

DOI OpenAlex
Recreational Ketamine Use among Individuals with Opioid Use Disorder: Demographics, Motivations, and Polysubstance Use (2025)

1 citation DOI OpenAlex
Pharmaceutical Stimulant Diversion, 2002-2022: Data from a National Sample of Law Enforcement and Regulatory Agencies (2025)

DOI OpenAlex
The Informal, Non-Prescribed Use of Antiretroviral Medications for PrEP Among a National US-Based Sample of Gay, Bisexual, and Other Men Who Have Sex with Men: A Cross-Sectional Study (2024)

DOI OpenAlex
Understanding Ketamine Use in Treatment-Seeking Persons With Opioid Use Disorder (2024)

DOI OpenAlex
GABAPENTIN UTILIZATION AMONG BUPRENORPHINE-PRESCRIBED INDIVIDUALS WITH OPIOID USE DISORDER AND ASSOCIATED RISK OF OVERDOSE (2024)

DOI OpenAlex
Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States (2024)

DOI OpenAlex
Geographic and Racial/Ethnic Differences in Access to Methamphetamine Detoxification Services, United States, 2021 (2024)

4 citations DOI OpenAlex
The impact of socio-environmental factors on doxycycline post-exposure prophylaxis awareness in the US: a cross-sectional study (2024)

12 citations DOI OpenAlex
Stigma Related to the Non-Medical Use and Diversion of Prescription Stimulant Drugs: Should We Care (2024)

1 citation DOI OpenAlex
Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder (2023)

8 citations DOI OpenAlex
Law enforcement experiences with gabapentin: non-medical use, diversion, and state controlled substances laws (2023)

2 citations DOI OpenAlex
Associations Between Kratom-Related State Policy Environments and Kratom Use in a Nationally Representative Population in the United States (2023)

10 citations DOI OpenAlex